PCN40 COST ANALYSIS OF MANAGING ADVERSE EVENTS IN THE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN PORTUGAL- A COMPARISON OF BEVACIZUMAB IN COMBINATION WITH INTERFERON ALFA-2A AND SUNITINIB
Nov 1, 2010, 00:00
10.1016/S1098-3015(11)71936-2
https://www.valueinhealthjournal.com/article/S1098-3015(11)71936-2/fulltext
Title :
PCN40 COST ANALYSIS OF MANAGING ADVERSE EVENTS IN THE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN PORTUGAL- A COMPARISON OF BEVACIZUMAB IN COMBINATION WITH INTERFERON ALFA-2A AND SUNITINIB
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)71936-2&doi=10.1016/S1098-3015(11)71936-2
First page :
A258
Section Title :
RESEARCH POSTER ABSTRACTS
Open access? :
No
Section Order :
92